QUESTIONS| Event Date/Time: Jan 31, 2011 | End Date/Time: Feb 01, 2011 |
Report as SpamDescription
SMi is proud to announce their latest Biomarkers Summit. Taking place on the 31st January and 1st February 2011 in London, this conference promises to be the largest and most comprehensive Biomarker event run by SMi Group to date.
It is now clear that the use of Biomarkers is an integral part in the future of medicine. With rising development costs and a declining rate of new drug discovery, pharmaceutical companies are now incorporating Biomarker strategies into all new R&D processes.
Key areas that will be addressed are: Bioinformatics, Preclinical Biomarker R&D, Translational Biomarkers, and Personalised Medicine.
Our exceptional speaker line-up includes:
• Hans Winkler, Senior Director and Global Head, Oncology Biomarkers, Johnson & Johnson
• Mark Fidock, Associate Research Fellow, Head of Quantitative Biomarkers, Pfizer
• Huseyin Mehmet, Director of Exploratory Biomarkers, Diabetes, Merck
• Fernando Ulloa-Montoya, Head of Molecular Biology Technology Group, GlaxoSmithKline
• Ziad Taib, Statistical Science Director, Astrazeneca
• Karen Asin, Director, Translational Pharmacology, Takeda
• Andrew Payne, Senior Group Leader, Cellular Sciences, UCB
• Ge Ruigt, Director Experimental Medicine Neuroscience, Merck
And much more....
It is now clear that the use of Biomarkers is an integral part in the future of medicine. With rising development costs and a declining rate of new drug discovery, pharmaceutical companies are now incorporating Biomarker strategies into all new R&D processes.
Key areas that will be addressed are: Bioinformatics, Preclinical Biomarker R&D, Translational Biomarkers, and Personalised Medicine.
Our exceptional speaker line-up includes:
• Hans Winkler, Senior Director and Global Head, Oncology Biomarkers, Johnson & Johnson
• Mark Fidock, Associate Research Fellow, Head of Quantitative Biomarkers, Pfizer
• Huseyin Mehmet, Director of Exploratory Biomarkers, Diabetes, Merck
• Fernando Ulloa-Montoya, Head of Molecular Biology Technology Group, GlaxoSmithKline
• Ziad Taib, Statistical Science Director, Astrazeneca
• Karen Asin, Director, Translational Pharmacology, Takeda
• Andrew Payne, Senior Group Leader, Cellular Sciences, UCB
• Ge Ruigt, Director Experimental Medicine Neuroscience, Merck
And much more....
Venue
Additional Information
Register for the half day post-conference workshop:
Fit for Purpose Biomarkers: From Bench to Bedside
Taking place on the 2nd February 2011 at the Crowne Plaza City hotel in London.
Hosted by Eric Culbert, Executive Director of BioScience Innovations.
This interactive workshop will highlight the nature and requirements of the different classes of Biomarkers, the technologies most suited to developing Biomarkers, and discuss case studies of Biomarker development and implementation which will help illuminate the key issues which can arrive during the journey from bench to bedside.
